5α-Reductase Inhibitors Impact Prognosis of Urothelial Carcinoma

    September 2020 in “ BMC Cancer ”
    Chien-Sheng Wang, Ching‐Chia Li, Yung‐Shun Juan … Hsiang‐Ying Lee
    Studysummary This retrospective cohort study found that patients using 5α-reductase inhibitors had reduced bladder cancer-related mortality compared to nonusers, with no significant effect on bladder cancer recurrence or upper tract urothelial carcinoma mortality.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on bmccancer.biomedcentral.com →
    Discuss this study in the Community →

    Research cited in this study 3

    1. Finasteride Does Not Prevent Bladder Cancer: A Secondary Analysis of the Medical Therapy for Prostatic Symptoms Study Urologic Oncology: Seminars and Original Investigations · 2018
    2. Bladder Cancer Survival of Men Receiving 5α-Reductase Inhibitors The Journal of Urology · 2018
    3. Expression of AR, 5αR1 and 5αR2 in Bladder Urothelial Carcinoma and Relationship to Clinicopathological Factors Life sciences · 2017